Resultados de búsqueda - Günter Fingerle‐Rowson

Limitar resultados
  1. 1
    A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

    A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies por Kensei Tobinai, Christian Klein, Naoko Oya, Günter Fingerle‐Rowson

    Publicado 2016
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  2. 2
    Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy

    Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy por Günter Fingerle‐Rowson, Matthias Angstwurm, R Andreesen, H.W.L. Ziegler-Heitbrock

    Publicado 1998
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  3. 3
    Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response

    Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response por Robert A. Mitchell, Hong Liao, Jason Chesney, Günter Fingerle‐Rowson, John A. Baugh, John R. David, Richard Bucala

    Publicado 2001
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  4. 4
    Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression

    Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression por Ramona Schulz, Natalia Marchenko, Lena Holembowski, Günter Fingerle‐Rowson, Marina Pešić, Lars Zender, Matthias Dobbelstein, Ute M. Moll

    Publicado 2012
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    Regulation of Macrophage Migration Inhibitory Factor Expression by Glucocorticoids in Vivo

    Regulation of Macrophage Migration Inhibitory Factor Expression by Glucocorticoids in Vivo por Günter Fingerle‐Rowson, Peter D. Koch, Rachel Bikoff, Xinchun Lin, Christine N. Metz, Firdaus S. Dhabhar, Andreas Meinhardt, Richard Bucala

    Publicado 2003
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Macrophage Migration Inhibitory Factor and CD74 Regulate Macrophage Chemotactic Responses via MAPK and Rho GTPase

    Macrophage Migration Inhibitory Factor and CD74 Regulate Macrophage Chemotactic Responses via MAPK and Rho GTPase por Huapeng Fan, Pam Hall, Leilani L. Santos, Julia L. Gregory, Günter Fingerle‐Rowson, Richard Bucala, Eric F. Morand, Michael J. Hickey

    Publicado 2011
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  7. 7
    Macrophage Migration Inhibitory Factor Inhibits the Antiinflammatory Effects of Glucocorticoids via Glucocorticoid‐Induced Leucine Zipper

    Macrophage Migration Inhibitory Factor Inhibits the Antiinflammatory Effects of Glucocorticoids via Glucocorticoid‐Induced Leucine Zipper por Huapeng Fan, Wenping Kao, Yuan Yang, Ran Gu, James Harris, Günter Fingerle‐Rowson, Richard Bucala, Devi Ngo, Élaine Beaulieu, Eric F. Morand

    Publicado 2014
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting

    The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting por Günter Fingerle‐Rowson, Oleksi Petrenko, Christine N. Metz, Thomas G. Forsthuber, Robert A. Mitchell, Ralf Huss, Ute M. Moll, Werner Müller, Richard Bucala

    Publicado 2003
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice

    Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice por Leilani L. Santos, Huapeng Fan, Pam Hall, Devi Ngo, Charles R. Mackay, Günter Fingerle-Rowson, Richard Bucala, Michael J. Hickey, Eric F. Morand

    Publicado 2010
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  10. 10
    Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis

    Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis por Lara J. Herrero, Michelle Nelson, Anon Srikiatkhachorn, Ran Gu, Surapee Anantapreecha, Günter Fingerle‐Rowson, Richard Bucala, Eric F. Morand, Leilani L. Santos, Suresh Mahalingam

    Publicado 2011
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury

    The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury por Dake Qi, Kwame Atsina, Lintao Qu, Xiaoyue Hu, Xiaohong Wu, Bin Xu, Marta Piecychna, Lin Leng, Günter Fingerle‐Rowson, Jiasheng Zhang, Richard Bucala, Lawrence H. Young

    Publicado 2014
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis

    Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis por Ran Gu, Leilani L. Santos, Devi Ngo, Huapeng Fan, Preetinder P. Singh, Günter Fingerle‐Rowson, Richard Bucala, Jiake Xu, Julian M.W. Quinn, Eric F. Morand

    Publicado 2015
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  13. 13
    Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study

    Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study por Valentin Goede, Kirsten Fischer, Anja Engelke, Rudolf Schlag, Stéphane Leprêtre, Luis Felipe Casado Montero, Marco Montillo, Chris Fegan, Elina Asikanius, K. Humphrey, Günter Fingerle‐Rowson, Michael Hallek

    Publicado 2015
    Enlace del recurso
    Carta
    Agregar a favoritos
    Guardado en:
  14. 14
    Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

    Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions por Ciara L. Freeman, Franck Morschhauser, Laurie H. Sehn, Mark Dixon, Richard Houghton, Thierry Lamy, Günter Fingerle‐Rowson, Elisabeth Wassner-Fritsch, John G. Gribben, Michael Hallek, Gilles Salles, Guillaume Cartron

    Publicado 2015
    Enlace del recurso Enlace del recurso
    Carta
    Agregar a favoritos
    Guardado en:
  15. 15
    MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model

    MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model por Pathricia V. Tilstam, Wibke Schulte, Thomas Holowka, Bong‐Sung Kim, Jessica Nouws, Maor Sauler, Marta Piecychna, Georgios Pantouris, Elias Lolis, Lin Leng, Jürgen Bernhagen, Günter Fingerle‐Rowson, Richard Bucala

    Publicado 2021
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  16. 16
    Macrophage Migration Inhibitory Factor (MIF) Enzymatic Activity and Lung Cancer

    Macrophage Migration Inhibitory Factor (MIF) Enzymatic Activity and Lung Cancer por Leona Mawhinney, Michelle E. Armstrong, Ciaran O’Reilly, Richard Bucala, Lin Leng, Günter Fingerle‐Rowson, Darren Fayne, Michael P. Keane, Aisling Tynan, Lewena Maher, Gordon Cooke, David G. Lloyd, Helen Conroy, Seamas C. Donnelly

    Publicado 2014
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  17. 17
    Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study

    Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study por Christopher R. Bolen, Magdalena Klánová, Marek Trněný, Laurie H. Sehn, Jie He, Jing Tong, Joseph N. Paulson, Eugene Kim, Umberto Vitolo, Alice Di Rocco, Günter Fingerle‐Rowson, Tina Nielsen, Georg Lenz, Mikkel Z. Oestergaard

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  18. 18
    Macrophage Migration Inhibitory Factor Enzymatic Activity, Lung Inflammation, and Cystic Fibrosis

    Macrophage Migration Inhibitory Factor Enzymatic Activity, Lung Inflammation, and Cystic Fibrosis por Huzaifa Adamali, Michelle E. Armstrong, Anne Marie McLaughlin, Gordon Cooke, Edward F. McKone, Christine Costello, Charles G. Gallagher, Lin Leng, John A. Baugh, Günter Fingerle‐Rowson, Richard Bucala, Paul McLoughlin, Seamas C. Donnelly

    Publicado 2012
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  19. 19
    Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

    Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Rando... por Sebastian Böttcher, Matthias Ritgen, Kirsten Fischer, Stephan Stilgenbauer, Raymonde M. Busch, Günter Fingerle‐Rowson, Anna Maria Fink, Andreas Bühler, Thorsten Zenz, Michael Wenger, Myriam Mendila, Clemens‐Martin Wendtner, Barbara Eichhorst, Hartmut Döhner, Michael Hallek, Michael Kneba

    Publicado 2012
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  20. 20
    A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

    A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL por Natalie Dimier, Paul Delmar, Carol Ward, Rodica Morariu-Zamfir, Günter Fingerle‐Rowson, Jasmin Bahlo, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Jacques J. M. van Dongen, Matthias Ritgen, Sebastian Böttcher, Anton W. Langerak, Michael Kneba, Michael Hallek

    Publicado 2017
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: